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ABSTRACT 
Anti-self/tumor T cell function can be improved by increasing TCR-peptide MHC 
(pMHC) affinity within physiological limits, but paradoxically further increases (KD 
< 1µM) lead to drastic functional declines. Using human CD8+ T cells engineered 
with TCRs of incremental affinity for the tumor antigen HLA-A2/NY-ESO-1, we 
investigated the molecular mechanisms underlying this high affinity-associated loss 
of function. As compared with cells expressing TCR affinities generating optimal 
function (KD; 5 to 1 µM), those with supraphysiological affinity (KD; 1 µM to 15 nM) 
showed impaired gene expression, signaling and surface expression of 
activatory/costimulatory receptors. Preferential expression of the inhibitory receptor 
programmed cell death-1 (PD-1) was limited to T cells with the highest TCR affinity, 
correlating with full functional recovery upon PD-L1 blockade. In contrast, 
upregulation of the Src homology 2 domain-containing phosphatase 1 (SHP-
1/PTPN6) was broad, with gradually enhanced expression in CD8+ T cells with 
increasing TCR affinities. Consequently, pharmacological inhibition of SHP-1 with 
sodium stibogluconate augmented the function of all engineered T cells, and this 
correlated with the TCR affinity-dependent levels of SHP-1. These data highlight an 
unexpected and global role of SHP-1 in regulating CD8+ T cell activation and 
responsiveness, and support the development of therapies inhibiting protein tyrosine 
phosphatases to enhance T cell mediated immunity.  
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INTRODUCTION 
CD8+ T cell responses rely on the specific recognition by T cell receptors (TCRs) of 
small immunogenic peptides presented in the context of MHC class I molecules at the 
surface of infected or transformed cells. Binding of TCR to peptide-MHC is 
characterized by relatively low molecular affinity (100 µM to 1 µM) and high 
specificity and sensitivity, thus enabling T cells to detect rare antigenic epitopes on 
antigen presenting cells (APC) (1). Due to mechanisms of central and peripheral 
tolerance, circulating autoreactive T cells recognizing self/tumor associated antigens 
typically have TCR-pMHC affinities at the lower end of the physiological range 
and/or are maintained in unresponsive functional states when compared with 
pathogen Ag-specific T cells. This might in part explain why tumor-reactive T cell 
responses detected in cancer patients often fail to control or eliminate advanced 
disease (2). 
Adoptive cell transfer (ACT) of T cells engineered to express TCRs of increased 
affinity for tumor antigens represents an attractive immunotherapeutic approach to 
induce and boost immune reactivity toward poor immunogenic tumors (3). Numerous 
studies suggest that enhancing TCR-pMHC interactions (half-life and affinity) would 
endow T cells with higher functional and protective capacity (4). However, it was 
also shown that T cells engineered with TCR of very high supraphysiological affinity 
for pMHC (KD < 1 nM) loose antigen specificity and become cross-reactive or 
alloreactive (5-7). As such, TCR optimization through affinity alterations has to 
include the careful evaluation of optimal T cell responsiveness, to ensure the safety of 
TCR-engineered T cells in clinical trials (3).  
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Recently, we characterized the functional impact of TCR-pMHC binding strength by 
using a panel of human CD8+ T cells engineered through structure-based rationally-
designed TCRs of incremental affinity for the self/tumor antigen A2/NY-ESO-1157-165  
(8-11). At low peptide dose stimulation, T cells with TCR affinities ranging in the 
upper physiological limit (KD from 5 µM to 1 µM) display higher biological 
responses, when compared with T cells expressing the wild-type (WT) TCR (KD at 
21.4 µM) (11). Strikingly, tumor-reactive T cells expressing TCRs of 
supraphysiological affinities (KD from 1 µM to 15 nM) show drastic functional 
decline irrespective of CD8 co-engagement, which is not associated with loss of 
antigen specificity (11). Similarly, other studies reported that T cells with TCR-
pMHC affinities and/or half-lives extending above the natural range exhibit 
attenuated T cell activation upon TCR triggering, as well as impaired expansion 
potential and responsiveness (12-16).  
To identify the molecular mechanisms underlying these functional defects, we 
characterized global gene expression, signaling pathways and activatory/inhibitory 
membrane receptors on human CD8+ T cells engineered with TCRs of incremental 
affinity for HLA-A2/NY-ESO-1. We describe how the inhibitory receptor PD-1 and 
the Src homology 2 domain-containing phosphatase 1 (SHP-1) are involved in 
restricting T cell function in TCR-engineered CD8+ T cells. Strikingly, SHP-1 
mediated a gradual functional inhibition of CD8+ T cells, along TCR binding affinity, 
independently of PD-1 involvement. Together, these data indicate that, in the context 
of adoptive cell therapy, TCR-mediated SHP-1 signaling may counter regulate T cell 
responses, by limiting the potential cytotoxic effect of TCR-optimized CD8+ T cells 
against self/tumor antigens. 
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RESULTS 
Impaired function of human primary CD8+ T cells expressing self/tumor-specific 
TCRs of supraphysiological affinity 
Using a panel of affinity-optimized HLA-A*0201-restricted NY-ESO-1157-165-
specific TCR (BC1) variants with gradually increased affinity of up to 1400-fold 
from the native TCR (Supplemental Table 1; (8, 9)), we previously found that 
maximal biological activity occurred within a well-defined affinity window with KD 
ranging from 5 to 1 µM (10, 11). Importantly, under low peptide stimulation 
conditions, cellular activity, including Ca2+ mobilization capacity (Figure 1A) and 
tumor cell killing (Figure 1B), was globally attenuated for T cells expressing either 
TCRs of very low (KD >100 µM; V49I) or of supraphysiological (KD < 1 µM; TMα, 
QMα and wtc51m) affinities. Conversely, high concentrations of NY-ESO-1157-165 
peptide loaded on APCs restored the Ca2+ mobilization capacity of CD8 T cells with 
supraphysiological TCRs (Supplemental Figure 1), consistent with our recent report 
(11). Similar data were obtained independently of stimulation with peptide-pulsed 
APCs or A2/peptide multimers. This functional decline was not caused by lower TCR 
expression as engineered CD8+ T cells and α-TCR knockout SUP-T1 cells expressed 
comparable surface levels of TCRβ chain (BV13.1) and of overall TCRαβ chains 
(Figure 1C, Supplemental Figure 2A).  
Upon short-term peptide stimulation, we observed substantial TCR down-regulation 
(reduced multimer fluorescence; Figure 1E) in all engineered CD8+ T cells 
independently of their TCR affinities (e.g. optimal versus supraphysiological). TCR 
down-modulation was assessed either by multimer fluorescence (Figure 1E) or by 
staining with an anti-BV13 mAbs (Supplemental Figure 2). In contrast, reduced CD8 
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co-receptor expression (Figure 1D; Supplemental Figure 2) was primarily found in T 
cells expressing TCRs mediating maximal/optimal function (A97L, DMβ, TMβ) 
rather than in T cells of supraphysiological TCR affinity (TMα, wtc51m). Altogether, 
our data further emphasize the paradoxical status of these NY-ESO-1 specific T cells 
expressing very high TCR affinities with impaired functionality despite retaining 
robust surface binding TCR avidity and TCR down-regulation capacity upon 
stimulation (Figure 1, (10, 11)). These findings suggest the presence of potential 
mechanisms controlling T cell activation, signaling and subsequent functionality.  
 
Altered gene expression profiles in CD8+ T cells with TCRs of supraphysiological 
affinity following antigen-specific stimulation 
In order to uncover the molecular mechanisms involved in the impaired functional 
responsiveness of cells bearing supraphysiological TCRs, we performed a genome-
wide microarray analysis on primary CD8+ T cells expressing the panel of TCR 
variants following low dose of A2/NY-ESO-1 specific multimer stimulation (Figure 
2A). We compared the global gene expression levels of all samples before and after 6 
hours of stimulation, and found 538 gene probes showing at least a two-fold 
differential expression (data not shown). Similar gene expression patterns were 
observed between engineered T cells belonging to the same culture conditions 
(unstimulated versus 6 hr-stimulated), and could accordingly be defined within two 
distinct clusters or profiles. However, unsupervised hierarchical clustering revealed 
that the 6 hr-stimulated T cells expressing infra- (V49I) and supra-physiological 
(wtc51m) affinity TCRs both clustered with the unstimulated T cells (Figure 2A).  
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To obtain a gene signature of optimal T cell activation, we compared the gene 
expression profiles of the four TCR-transduced CD8+ T cells known to produce 
maximal function (G50A, A97L, DMβ, TMβ) before and after 6 hr activation. With 
this strategy, we identified 524 differentially expressed genes and classified them 
according to six general Gene Ontology (GO) terms. The average absolute log2 fold 
change (0 to 6 hr) of the genes within each GO term is represented in Figure 2B. 
Remarkably, all GO terms (immune response, T cell activation, cell proliferation, 
signaling, gene expression and apoptosis) had the same overall outline demonstrating 
a drastic under-representation of the gene expression within V49I and wtc51m TCR 
variants. The average absolute fold change was progressively increased from low to 
optimal TCR affinity, before declining in T cells with supraphysiological TCR 
variants (TMα and wtc51m). Interestingly, the pattern of gene expression profile 
related to apoptosis strongly correlated to the one observed following A2/peptide 
multimer stimulation and staining with Annexin-V (11), with highest levels of 
apoptosis for CD8+ T cells expressing optimal TCRs. In addition, several key genes 
involved in T cell activation (e.g CRTAM, IFNG and IL2RA) as well as costimulatory 
molecules (e.g. TNFRSF18, TNFRSF4, TNFRSF9) showed a 2-fold or greater 
change, and displayed the same overall bell-shape profile following 6h-stimulation 
(Figure 2C). No major changes in genes classified to the GO terms were observed at 
baseline in un-stimulated CD8+ T cells (Supplemental Figure 3).  
Similar to the functional data (Figure 1), gene expression analyses revealed that T 
cells engineered with TCR of infra- or supra-physiological affinity clustered together 
and failed to properly modulate their transcriptome upon specific TCR triggering. 
Conversely, the transcriptional gene signatures of CD8+ T cells expressing optimal 
TCR variants (G50A, A97L, DMβ and TMβ) revealed drastic global changes (up- or 
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down-regulation) in gene expression levels following short-term antigen-specific 
stimulation, supporting enhanced T cell responsiveness. 
 
Affinity of TCR-pMHC interaction impacts on the intensity and duration of TCR-
mediated intracellular signaling 
To gain functional insights into the molecular mechanisms underlying altered gene 
expression profiling associated with very low or very high TCR affinities (Figure 2), 
we explored the impact of TCR affinity on cell signaling. We assessed the activation 
levels of ZAP-70, a proximal activatory molecule of TCR signaling and of the distal 
MAPK family members ERK1/2 (p38). SUP-T1 and CD8+ T cells expressing TCR 
variants were stimulated with A2/NY-ESO-1-specific multimers and levels of 
phosphorylated ZAP-70 (pY319) and ERK1/2 (pT202/pY204 ERK1; pT185/pY187 
ERK2) were quantified in kinetic analyses. Upon specific stimulation, we found 
differential levels of ZAP-70 phosphorylation intensity and duration correlating with 
TCR affinity variants (Figure 3, Supplemental Figure 4). V49I-transduced T cells 
showed only transient and low levels of ZAP-70 phosphorylation, whereas cells 
expressing TCR variants mediating optimal functions (e.g. A97L, DMβ) generated 
fast and sustained ZAP-70 phosphorylation. Importantly, in CD8+ (Figure 3C, 
Supplemental Figure 4) and SUP-T1 (Figure 3, A and B) cells expressing 
supraphysiological TCR affinities (e.g. QMα and wtc51m), ZAP-70 phosphorylation 
declined rapidly and substantially following specific stimulation.  
ERK1/2 phosphorylation profiles corresponded with those observed for ZAP-70 
phosphorylation, with an overall increase in the signaling intensities depending as 
well on the TCR affinity variants. Maximal phosphorylation was found for TCR 
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variants of optimal function, while T cells with supraphysiological TCRs showed 
mostly a transient and rapid loss of ERK1/2 phosphorylation following TCR 
stimulation (Figure 3, Supplemental Figure 4). Together, the transgenic TCR affinity 
strongly impacted on both the intensity and the duration of ZAP-70 and ERK1/2 
phosphorylations. Importantly, CD8+ T cells expressing supraphysiological TCRs 
affinity presented a drastically reduced activation of key TCR downstream signaling 
pathways (Ca2+ and MAPK), and this occurred at a very proximal step in the TCR 
signaling cascade (ZAP-70). Conversely, the low cell signaling observed in V49I-
expressing T cells nicely correlated with the poor intrinsic binding avidity of this 
particular TCR (10, 11). 
 
Impact of TCR-pMHC affinity on the expression of co-activatory/inhibitory receptors 
Since global genome profiling revealed reduced expression of genes involved in 
costimulatory/activatory molecules in supraphysiological T cells (Figure 2), we next 
focused on measuring the surface expression levels of CD28, as well as CD27 and 
HVEM and their respective ligands (CD70 and BTLA) (Figure 4A). Under steady-
state conditions, most of the TCR transduced CD8+ T cells, including cells with the 
lowest TCR-affinity variant (V49I) expressed similar levels of CD28, as well as of 
CD27 and HVEM with their respective ligands. Strikingly, T cells bearing 
supraphysiological TCR affinity (wtc51m) had statistically significant lower 
expression of CD28, HVEM and CD70, all three involved in T cell activation 
signaling. In contrast, BTLA, known to inhibit T cell function (17), was expressed at 
the highest levels in wtc51m-expressing T cells (Figure 4A). No significant 
differences in CD8α expression were found (data not shown), yet there was a trend of 
lower expression of the CD8β in T cells with supraphysiological TCRs (Figure 4A). 
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Significantly reduced expression of Granzyme B and Perforin (Figure 4B) was also 
found in the latter T cells (wtc51m), consistent with their attenuated killing capacities 
(Figure 1B). Importantly, similar data were obtained when CD8+ T cells were 
stimulated with A2/NY-ESO-1-specific multimers over a 24 hr- and 48 hr-period of 
time (data not shown). Overall, these data further support the notion that CD8+ T 
cells expressing supraphysiological TCR affinities likely exhibit molecular 
mechanisms that actively down-regulate surface co-activatory molecules/receptors. 
This was readily observed under steady-state conditions.  
 
Engineered T cells of supraphysiological TCR affinity show enhanced expression of 
PD-1 correlating with full functional recovery upon PD-L1 blockage 
CD8+ T cells express multiple negative regulators, such as BTLA, PD-1 and CTLA-
4, which have been proposed to play central roles in preventing uncontrolled T cell 
activation and autoimmunity during inflammatory responses (18). Therefore, we 
sought to determine whether PD-1 could functionally regulate CD8+ T cells 
expressing TCRs of increased affinities. We assessed PD-1 expression in un-
stimulated TCR engineered T cells (Figure 5, B and C). Comparable with mRNA 
data (Figure 5A), elevated PD-1 levels were exclusively found in CD8+ T cells of 
highest supraphysiological affinity (wtc51m). Of note, PD1 mRNA fold-change at 6 
hr stimulation showed the same overall bell-shape profile with maximal expression in 
T cells mediating optimal function (A97L, DMβ and TMβ), thereby indicating that 
PD-1 expression can also be induced shortly after antigen-specific TCR stimulation 
(Figure 5A). No significant differences were found in expression levels of PD-1 
ligand PD-L1 (Figure 5B) and CTLA-4 (data not shown).  
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Since PD-L1 surface expression was highly comparable across the TCR affinity 
panel, we next evaluated the biological significance of PD-1 expression on T cell 
responsiveness by blocking PD-1/PD-L1 interaction. All transduced CD8+ T cells 
were incubated with PD-L1 neutralizing antibody prior to LAMP1/CD107a 
degranulation assays (Figure 5, D and E). After 4 hr triggering with the NY-ESO-1 
peptide, PD-L1 blockade had no effect on the CD107a degranulation in most of CD8+ 
T cells, with the exception of the supraphysiological TCR variant (wtc51m) that 
exhibited an increased proportion of degranulating cells, even reaching similar levels 
to the other TCR variants (Figure 5D). Relative CD107a degranulation activity 
further confirmed that blocking the PD-1/PD-L1 pathway led to full functional 
recovery in the supraphysiological T cells (Figure 5E). Collectively, our data revealed 
preferential expression of PD-1 in supraphysiological CD8+ T cells, i.e. those with 
TCRs in the nanomolar range (wtc51m). Furthermore, PD-L1 blockade restored 
CD107a degranulation in PD-1high expressing cells, demonstrating its key implication 
in the functional regulation of those T cells. 
 
Enhanced expression of SHP-1 phosphatase in a TCR-affinity dependent manner  
SHP-1 and SHP-2 phosphatases can be recruited by multiple inhibitory surface 
receptors in T cells, and inhibit TCR signaling (19), through dephosphorylation of 
proximal signaling targets (e.g. LCK, ZAP-70, CD3ζ). Under un-stimulated 
conditions, SHP1 gene expression was progressively increased from low to high TCR 
affinity (Figure 6A; baseline). We characterized the expression levels of total SHP-1 
protein and its phosphorylated activatory form Y536 (20) as well as of total SHP-2 
protein (Figure 6, Supplemental Figure 5). Maximum levels of SHP-1 
phosphorylation were detected in both CD8+ and SUP-T1 T cells transduced with 
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supraphysiological TCR variants (e.g. QMα and wtc51m) after antigen-specific 
stimulation, and already under steady-state conditions. Importantly, transient levels of 
phosphorylated SHP-1 were also enhanced in the other TCR variants upon 
stimulation, yet never reached those observed in QMα and wtc51m-transduced T 
cells. Total SHP-1 protein revealed expression patterns that followed the same TCR 
binding hierarchy, with intermediate and highest levels found for optimal and 
supraphysiological TCR affinities, respectively (Figure 6). In CD8+ T cells, the weak 
binding TCR ligand V49I was also able to trigger SHP-1 protein expression and 
phosphorylation, consistent with a previous report (21) showing that SHP-1 is 
involved in antagonist-mediated inhibition. Thus, differing to PD-1 expression, SHP-
1 phosphatase was found up-regulated in a TCR affinity-dependent manner with 
substantial expression levels readily found in T cells of optimal TCRs affinities. A 
comparable trend was observed for total SHP-2 expression (Supplemental Figure 5). 
Finally, we assessed the expression levels of miR-181a and miR-155 (Figure 6E), 
two micro RNA, mostly known to impact, respectively, on lymphocyte development 
and function (22, 23). Following specific TCR stimulation, only minor changes in 
miR-181a expression were found within the engineered panel of CD8+ T cells. This 
highly contrasted with the strong induction in pri-miR-155 (BIC transcript) and miR-
155 expression observed within T cells expressing WT and optimal TCR affinities 
(e.g. A97L, DMβ).  
 
Impact of pharmacological SHP-1 phosphatase inhibition on degranulation and 
cytotoxicity of TCR engineered CD8+ T cells. 
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Sodium stibogluconate (SSG) is widely used to treat visceral leishmaniasis and was 
recently identified as an important clinically suitable protein tyrosine phosphatase 
inhibitor in cancer patients (24, 25). Notably, SSG has been shown to selectively 
inhibit protein tyrosine phosphatases, among which SHP-1 was the most sensitive 
(26). Given the elevated levels of SHP-1 and SHP-2 protein expression within 
engineered CD8+ T cells, we next examined whether SSG treatment might improve 
their function, irrespectively of PD-1 expression (Figure 7). We incubated the CD8+ 
T cells in the presence or absence of SSG for 3 days, at a concentration (50 µg/ml) 
shown to partially inhibit SHP-2 activity as well (26). Following pharmacological 
inhibition of SHP-1/SHP-2, increased degranulation potential (Figure 7, A and B) 
was found within the whole T cell panel, except for cells expressing the infra-
physiological TCR affinity V49I. Importantly, functional recovery was further 
validated in target cell killing experiments (Figure 7, C and D), and correlated well 
with the affinity-dependent levels of SHP-1 phosphatase found in T cells. Indeed, and 
in agreement with their stronger phosphorylation levels, supraphysiological T cells 
showed better killing recovery capacity than compared to WT and optimal T cells. 
Although we cannot formally exclude off-target effects of SSG treatment, these 
results support the notion that SHP-1 phosphatase (and eventually SHP-2) may 
mediate a gradual functional inhibition in TCR-engineered CD8+ T cells, depending 
on TCR affinity, but not necessarily on the degree of PD-1 involvement.  
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DISCUSSION 
The panel of rationally designed NY-ESO-1157-165-specific TCRs with incremental 
affinity (8, 9) provides a unique model to investigate the relationship between TCR 
affinity and T cell function, as well as its modulation by activatory/inhibitory co-
receptors and their signaling pathways. Here, we show that the impaired functionality 
recently observed in CD8+ T cells engineered with supraphysiological TCR affinities 
(KD < 1 µM) (11) was associated with a strong decrease in overall gene expression 
profile, intracellular signaling and surface expression of activatory TNFR 
superfamily members (Figures 2 to 4). Our major findings revealed that the T cell 
effectiveness of engineered CD8+ T cells was limited by at least two mechanisms. 
The first one was characterized by the preferential expression of PD-1 inhibitory 
receptor within T cells of highest supraphysiological TCR affinity (wtc51m variant), 
and this correlated in those cells with restored cell responsiveness upon PD-1/PD-L1 
blockade (Figure 5). The second one was associated with the gradual increased 
expression of SHP-1 phosphatase in a TCR affinity-dependent manner, from WT to 
very high TCR affinities (Figure 6). In contrast to PD-1/PD-L1 blockade 
experiments, pharmacological inhibition using sodium stibogluconate known to 
inhibit SHP-1 (and partially SHP-2) allowed further incremental gaining of cell 
function in engineered CD8+ T cells, according to their TCR binding affinity (Figure 
7).  
Adoptive cell therapy (ACT) using autologous T lymphocytes reprogrammed by 
TCR gene transfer aims to confer robust immune reactivity towards defined tumor-
associated antigen-bearing cells to which the endogenous T cell repertoire is weak or 
non-responsive. Recently, two clinical trials were conducted whereby autologous T 
cells transduced with affinity-enhanced TCRs specific for tumor-associated antigens 
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were adoptively transferred to patients with metastatic melanoma or sarcoma, and 
demonstrated objective clinical responses (27, 28). Robbins and colleagues (28) were 
the first to examine the in vivo efficacy of adoptively transferred autologous T cells 
transduced with the sequence-optimized 1G4 TCR specific for NY-ESO-1157-165. This 
genetically modified TCR possesses an affinity that lies just beyond the natural 
affinity range and confers maximal in vitro functionality with lowest cross-reactivity 
(6). In line with these observations, vaccination with peptide ligands of intermediate 
affinity yielded the most potent tumor-reactive CD8+ T cells in vivo, and best tumor 
growth control in BALB/c mice (15). Recently, Corse et al. further confirmed that 
peptide binding to the TCR with medium strength induced optimal in vivo CD4+ T 
cell activation and subsequent immune responses (12). Future directions involve 
integrating the vast knowledge acquired from the in vitro experimental studies into 
the context of in vivo immune responses and clinical trials of adoptive cell therapy 
(reviewed in (29)).  
The in silico structure-based approach allowed to rationally design sequence 
substitutions in the CDR2α and/or CDR2β and/or CDR3β loops, known to interact 
either with the MHC surface or the bound peptide (Supplemental Table 1; (8, 9), 
Zoete V., Irving M., and Michielin O., unpublished observations). We also included 
in this panel, the supraphysiological TCR variant wtc51m, previously identified by 
phage-display screening, with nanomolar range of affinity to the HLA-A2/NY-ESO-1 
complex (30). Importantly, and despite their impaired functionality, all engineered 
CD8+ T cells expressing supraphysiological TCRs of KD < 1 µM (TMα, QMα and 
wtc51m) retained a high degree of specificity towards the cognate pMHC target in 
functional assays (10, 11). An important finding in this study is that, only engineered 
T cells with the highest TCR affinity variant (wtc51m) up-regulated inhibitory 
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receptors (PD-1 and BTLA) and conversely down-regulated co-activatory receptors 
(CD28, HVEM, CD8β) (Figure 4 and 5). What remains intriguing is how such affine 
T cells control the expression of their activatory/inhibitory receptors readily under 
steady-state settings. One likely explanation is that, in contrast to the rational design 
approach ((8, 9), Zoete V., Irving M., and Michielin O., unpublished observations), 
gain in affinity for the wtc51m TCR variant resulted from multiple increased 
interactions with the HLA-A2 molecule, as this particular TCR contained up to four 
amino acid replacements within the CDR2β loop (30). Besides that, TCR surface 
expression also integrates and potentiates the effects of several variables/parameters 
including multiple coreceptors, TCR density, multivalent TCR clustering, and basal T 
cell activation state (reviewed in (4)). Together, weak but continuous TCR-A2 
specific interactions regardless of the nature of the bound peptide, may occur during 
the in vitro culture and periodic expansion of the transduced primary CD8+ T cells 
and SUP-T1 cells (both HLA-A2 positive) and may be sufficient to modulate 
activatory/inhibitory receptor expression already under resting culture conditions. 
Notably, these conditions are very similar to the in vitro culture of autologous T cells 
transduced to express TCRs against HLA-A2/tumor antigens and further expanded 
before ACT (28). Collectively, these data emphasize the potential impact of TCR-A2 
binding affinity in relation to membrane receptor expression, T cell activation, and 
signaling, and highlight the need to carefully assess TCR affinity/avidity in relation to 
its functional efficacy for optimizing the design of ACT and vaccination.   
An important aspect is to understand how T cells sense the differences in the strength 
of TCR-peptide/MHC interactions, as observed here within the panel of affinity-
optimized T cells. One of the current models (defined as the productive hit rate 
model) postulates that TCR-pMHC binding interactions need to be sufficiently long 
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to initiate productive TCR signaling and subsequent T cell activation (reviewed in 
(31)). It also integrates that TCR-pMHC bonds must be released quickly enough to 
enable serial triggering, to acquire strong signals upon multiple interactions between 
TCRs and the pMHC complex. As a consequence, the productive hit rate model 
proposes that very fast or very slow TCR-pMHC dissociation rates would reduce the 
activation potential of T lymphocytes (14). The findings that maximal function 
occurred within a well-defined affinity window (KD; 5 to 1 µM), and that above it, T 
cells engineered with supraphysiological TCR affinities responded less efficiently to 
antigen stimulation further support this model (11). Importantly, recent in vivo 
studies show that functional T cell responses are also largely influenced by the TCR 
ligand affinity/avidity and the amount of presented antigen (12, 32). These 
observations are compatible with the notion that T cell clonotypes with a broad range 
of TCR affinities/avidities may participate equally (codominantly) in immune 
responses, and that this may depend both on peptide-MHC potency and density (33).  
Beside the biophysical regulation imposed by the TCR-pMHC binding parameters, 
the recruitment of inhibitory receptors like PD-1 (programmed death-1) in tumor-
specific T cells of supraphysiological TCR affinity (wtc51m) reveals the presence of 
an additional level of control allowing to restrain effector function in those cells, such 
as observed in autoimmune or anti-tumoral responses. Engagement of PD-1 by PD-1 
ligand 1 (PD-L1) is thought to be critical in preventing activation of self-reactive T 
cells that have escaped thymic clonal deletion (18). Accordingly, PD-1-deficient mice 
spontaneously develop autoimmune diseases (34), while in humans a regulatory 
polymorphism in PD-1 is associated with susceptibility to systemic lupus 
erythematosus and multiple sclerosis (35, 36). Induction of PD-L1 ligand expression 
has also been described in various tumor cells as a mechanism of cancer immune 
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evasion (2). Furthermore, PD-1 expression is inducible in T cells following TCR 
stimulation, and may be involved in the suppression of T cell activation in vitro and 
in vivo (37). However, the molecular basis by which PD-1 inhibits T cell activation is 
not fully understood. A recent study by Yokosuka and colleagues showed that upon 
PD-L1 binding, ITIM-containing PD-1 could directly inhibit TCR-mediated signaling 
by recruiting SHP-2 phosphatase (38). 
SHP-1 phosphatase negatively regulates TCR signal transduction and T cell 
activation upon TCR engagement, and contributes to the setting of thresholds during 
thymocyte selection (19). Recently, SHP-1 was shown to limit the production of 
virus-specific effector CD8 T cells without impacting the formation of long-lived 
central memory cells (39). Furthermore, abrogation of SHP-1 expression in tumor-
specific T cells improved efficacy of adoptive immunotherapy by enhancing the 
effector function and accumulation of short-lived effector T cells in vivo (40). Here, 
we extend these findings by showing that SHP-1 phosphatase may represent an 
important regulatory molecule in CD8+ T cells engineered with incremental affinity 
TCR variants. Importantly, SHP-1 was found upregulated in a TCR affinity-
dependent manner with the highest levels in T cells with supraphysiological TCRs 
(Figure 6, Supplemental Figure 5). This suggests that SHP-1 may play a dual role and 
restricts not only T cell signaling at the very low range of TCR stimulation (e.g. with 
antagonist ligands) as previously described (21), but also at the higher range (e.g. 
with optimized and supraphysiological TCR affinity ligands). Our observations are 
further consistent with a recent study showing that B cell receptor (BCR) signaling 
was limited by SHP-1 activity in the most proliferating germinal center B cells, 
revealing a regulatory effect on the affinity-based selection of those cells (41). 
However, additional studies using SHP-1-specific small interfering RNA are still 
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needed to fully demonstrate the impact of SHP-1 in mediating functional inhibition of 
affinity-optimized T cells.  
Specific microRNAs have been shown to be critical for T cell development and 
function. For instance, transcriptional activation of miR-155 is detectable upon 
lymphocyte activation (42) and correlates with increased expression in human 
antigen-experienced CD8+ T cell subsets (23). Here we provide evidence that miR-
155 expression, but paradoxically not miR-181a, may be involved in modulating T 
cell function in TCR affinity-optimized CD8+ T cells. Thus, it will be of great 
importance to further explore the mechanisms by which miR-155 may influence cell 
activation and responsiveness along the TCR affinity range in peripheral T 
lymphocytes.  
CTLA-4 and PD-1 are two checkpoint inhibitory receptors that have become novel 
targets for treating cancer patients, as these molecules can be specifically blocked 
with antibodies (43). Consequently, antibodies against PD-1 and PD-L1 have entered 
phase 1 clinical trials, and initial results showing objective tumor regression are 
highly promising (44, 45). More recently, two phase 1 trials using the phosphatase 
inhibitor sodium stibogluconate (SSG) in combination with IFN-α2b have 
demonstrated safety and targeted inhibition in cancer patients (24, 25). Our findings 
highlight the critical role of SHP-1 expression among the whole panel of engineered 
CD8+ T cells. In particular, we show that targeting SHP-1 in T cells with optimal 
antitumor-specific TCRs (A97L, DMβ and TMβ) further augment their functional 
efficacy. These observations provide the rational for adoptive T cell therapy using 
affinity-optimized TCR variants combined with treatments blocking PD-1 and/or 
SHP1/2 phosphatases. 
    
 20 
METHODS 
Cell lines and primary CD8+ T cells  
TCR-α knockout SUP-T1 cells and HLA-A2+/TAP-deficient T2 cells were cultured 
in RPMI supplemented with 10% FCS, 10 mM Hepes, penicillin (100 U/ml) and 
streptomycin (100 µg/ml). Human primary HLA-A2+ CD8+ T lymphocytes were 
obtained following positive enrichment using anti-CD8-coated magnetic microbeads 
(Myltenyi Biotec), and cultured in RPMI supplemented with 8% HS and 150 U/ml 
recombinant human IL-2. Cell surface analysis and functional assays were always 
performed between day 10 and 15 post stimulation with 30 Gy irradiated PBMC as 
feeder cells and 1 µM PHA (Oxoid) as described before (10). 
 
NY-ESO-1-specific TCR αβ constructs, lentiviral production and cell transduction  
Cloning strategies and lentiviral production were performed as described previously 
(10, 11). The full-length codon-optimized TCR AV23.1 and TCR BV13.1 chain 
sequences of a dominant NY-ESO-1157-165 -specific T cell clone of patient LAU 155 
were cloned in the pRRL, third generation lentiviral vectors, as a hPGK-AV23.1-
IRES-BV13.1 construct. Structure-based amino acid substitutions were introduced 
into the wild-type (WT) TCR sequence using the QuickChange mutagenesis kit 
(Stratagene) and confirmed by DNA sequencing. Supernatant of lentiviral transfected 
293T cells were used to infect SUP-T1 or primary CD8+ T lymphocytes. PE-labeled 
A2/NY-ESO-1157-165 -specific multimers were used to sort transduced primary CD8+ 
T cells in order to enrich for multimer+ cells by flow cytometry (FACS Vantage SE 
machine; BD Biosciences). Integrated lentiviral copy number was relatively 
equivalent for each one of the TCR variants within each type of transduced cell; i.e. 
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8-10 lentivirus copies/genome of SUP-T1 cells and 1-2 copies/genome of CD8+ T 
cells, as described in (11). 
 
Flow cytometry analysis  
Levels of NY-ESO-1-specific BV13.1/AV23 TCR expression on SUP-T1 and CD8+ 
T cells were monitored with PE-labeled NY-ESO-1157-165-specific multimers (TC 
Metrix), FITC-conjugated BV13.1 antibody (Beckman Coulter) and FITC-conjugated 
pan-TCRαβ antibodies (Beckman Coulter) before each experiment as previously 
described (10). For CD8 and TCR down-regulation experiments, TCR-transduced 
CD8+ T cells were stimulated with 0.1 µg/ml unlabeled HLA-A2/NY-ESO-157-165-
specific multimers for 4 hours at 37°C, before staining with FITC-conjugated CD8 
and PE-labeled A2/NY-ESO-1157-165 multimers. The proportion (in %) of CD8+ T 
cells with reduced CD8 stainings as well as the mean fluorescence intensity (MFI) by 
multimer stainings was measured by flow cytometry (GalliosTM, Beckman Coulter). 
Staining of surface costimulatory molecules and co-activatory/inhibitory receptors 
was performed for 20 min at 4ºC using the fluorophore-conjugated antibodies listed 
in Supplemental Methods. Intracellular stainings were performed according to the 
manufacturer’s instructions. Data were acquired on a GalliosTM Flow Cytometer 
(Beckman Coulter) analyzed using FlowJoTM (TreeStar).  
 
Calcium flux assays upon NY-ESO-1 multimer stimulation 
5x104 TCR-transduced CD8+ T lymphocytes were loaded with 2 µM Indo 1-AM 
(Sigma-Aldrich) for 45 min at 37ºC. Cells were washed and resuspended in 250 µl 
prewarmed RPMI containing 2% FCS. Baseline was recorded for 30 sec before 1 
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µg/ml of unlabeled A2/NY-ESO-1 multimer was added to the cells. Intracellular Ca2+ 
flux was assessed during 5 min, under UV excitation and constant temperature of 
37ºC using a thermostat device on a LSR II SORP (BD Biosciences) flow cytometer. 
Indo-1(violet)/Indo-1(blue) 405/525 nm emission ratio was analyzed by FlowJo 
kinetics module software (TreeStar).  
 
Chromium release assays 
Specific antigen recognition lytic activity of the NY-ESO-1-specific CD8+ T 
engineered with TCR variants of increased affinities was assessed functionally in 4 
hours 51Cr-release assays against the melanoma cell lines NA8 (HLA-A2+/NY-ESO-
1-) as well as Me 275 and Me 290 (HLA-A2+/NY-ESO-1+). The percentage of 
specific lysis was calculated as follow: 100 × (experimental − spontaneous 
release)/(total − spontaneous release).  
 
Microarray analysis 
Primary CD8+ T cells (1x106) transduced with sequence-optimized NY-ESO-1-
specific TCR variants were cultivated in RPMI supplemented with 8% HS and 10 
U/ml rhIL-2 for 24 hours and left either unstimulated (baseline, 0 hr) or were 
stimulated with low dose 0.002 µg/ml unlabeled A2/NY-ESO-157-165-specific 
multimer for 6 hours at 37°C to avoid activation-induced cell death. The proportion 
of Annexin-V+ cells was < 10% (data not shown). After incubation, cells were 
washed with ice-cold PBS before quick freezing in liquid nitrogen. Frozen cell pellets 
were sent to Miltenyi Biotec GmbH and processed according to the vendor-
recommended protocol for gene expression analysis as described in Supplemental 
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Methods. The gene expression data described in this manuscript have been deposited 
in the NCBI Gene Expression Omnibus and are accessible through the GEO 
accession number (GSE42922).  
 
Western blot analysis 
For all experiments, 1x106 untransduced or TCR-transduced SUP-T1 and primary 
CD8+ T cells were either left unstimulated (baseline) or stimulated with 10 µg/ml 
unlabeled A2/NY-ESO-1157-165 multimers for the indicated time in a 37°C water bath 
before washing with ice-cold PBS and quick freezing in liquid nitrogen. Following 
cell extraction, proteins were separated by SDS-PAGE and subsequently probed with 
the following primary antibodies: goat anti-SHP-1 (C-19) (LabForce AG), rabbit anti-
pERK1/2 (Thr202/Tyr204) (D13.14.4E), mouse anti-ERK1/2 (3A7), rabbit anti-
pZAP-70 (Tyr319)/Syk(Tyr352), rabbit anti-ZAP-70 (99F2) (Cell Signaling 
Technology), rabbit anti-pSHP-1 (Tyr536) (ECM Biosciences), mouse anti-α-tubulin 
(B-5-1-2) (Sigma-Aldrich) and rabbit anti-actin (AA20-33) (Sigma-Aldrich). 
Quantification of specific bands was done using PhosphoImager software ImageJ and 
normalized to α-tubulin or actin expression levels.  
 
Quantitative PCR analysis for miR-155 and miR-181a expression 
TCR-transduced CD8+ T cells (1x106) were left either unstimulated (baseline, 0 hr) or 
stimulated with 0.01 µg/ml unlabeled A2/NY-ESO-1157-165 multimers for 6h, 24h and 
48h at 37oC under 10 U/ml rhIL-2 media conditions. Following incubation, cells were 
washed and total RNA was extracted with the miRVana kit (Ambion, Life 
Technologies), and mature microRNAs (hsa-miR-155, hsa-miR-181a and hsa-
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RNU48) were reverse transcribed with the TaqMan MicroRNA Reverse transcription 
kit (Applied Biosystems). Amplification and real time acquisition were performed 
using Universal PCR Master Mix (Applied Biosystems) in MicroAmp 384 well plates 
(Applied Biosystems) on a LightCycler 480 instrument (Roche Ltd.). Ct (RNU48) 
was subtracted to Ct (miR-155, miR-181a) to calculate relative expression (ΔCt).   
 
Functional PD-L1 blockade or pharmacological SHP-1/SHP-2 inhibition assays 
For PD-L1 blockade, 5x105 TCR-transduced CD8+ T cells were cultured in 500 µl 
RPMI complemented with 8% HS, 150 U/ml rhIL-2 at 37oC without (control) or with 
5 µg/ml PD-L1 blocking antibody (CD274 clone MIH1, eBioscience). Alternatively, 
50 µg/ml sodium stibogluconate (SSG) (Sb content; Santa Cruz Biotechnology, Santa 
Cruz, CA) was used for SHP-1/SHP-2 inhibition. After 3-4 days, 4x105 T cells were 
incubated at 37oC during 4 hours with 2x105 either unloaded T2 (control) or 10 µM 
NY-ESO-1-loaded T2 cells (E:T ratio 2:1) together with PE-Cy5 CD107a/LAMP-1 
(BD Biosciences) antibody. Acquisition was performed on a LSRI (BD Biosciences) 
or a Gallios (Beckman Coulter) instrument, and data was analyzed with FlowJo 
(TreeStar). For target cell killing experiments, TCR-transduced CD8+ T cells were 
incubated with 50 µg/ml SSG for 3-4 days as described above before assessing 
antigen-specific lytic activity in a 4-h 51Cr-release assay against Me 275 cells (HLA-
A2+/NY-ESO-1+) at a 10:1 and 3:1 effector:target (E:T) ratios. 
 
Statistics 
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For quantitative comparison, paired or unpaired Student’s t test  (2-sample 2-tailed 
comparison), as indicated, was performed using GraphPad Prism software; P < 0.05 
was considered as significant.  
 
Study procedure 
Human peripheral blood cells were obtained from healthy donors of the Blood 
Transfusion Center of the University of Lausanne, Switzerland. All donors had 
previously completed the Swiss National Medical questionnaire, to verify that they 
fulfilled the criteria for blood donation, and provided written informed consent for the 
use of blood samples in medical research after anonymization. 
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Figure 1. Functionality, TCRαβ surface expression levels and TCR/CD8 down-
regulation in CD8+ T cells engineered with self/tumor-specific TCR of incremental 
affinities.  
A. Ca2+ flux of TCR-transduced CD8+ T cells without (baseline) and with 1 µg/ml 
HLA-A2/NY-ESO-specific multimer stimulation. Maximal Ca2+ flux after ionomycin 
stimulation indicates equal capacity to mobilize calcium in all T cell variants. B. 
Cytotoxic activity (% of maximal killing) against Me 275 and Me 290 (HLA-
A2+/NY-ESO-1+) and Na8 (HLA-A2+/NY-ESO-1-) tumor cell lines at an effector 
target ratio of 10:1. C. Percentage of primary CD8+ T cells expressing the affinity-
optimized NY-ESO-1-specific TCRs as detected by A2/NY-ESO-1157-165-specific 
multimer staining (left panel). Cells with >80% multimer labeling were used for 
further analysis. Surface expression levels (in MFI) of TCR β-chain BV13.1 (middle) 
and total αβTCR (right) is shown for all CD8+ T transduced cells. D and E. Down-
regulation of CD8 coreceptor (D; in %) and TCR (E; in MFI) in engineered CD8+ T 
cells in the absence (baseline) or presence of 0.1 µg/ml unlabeled A2/NY-ESO-1-
specific multimer. Data from T cells with reduced CD8 expression (D; CD8 low) are 
shown in percent of total T cells (CD8 high and low). TCR down-regulation 
following stimulation (E) is depicted as dark gray histograms or columns.  
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Figure 2. Gene expression of CD8+ T cells engineered with TCR of incremental 
affinities. 
A. Microarray hierarchical clustering of gene expression intensities from the 538 
gene probes with statistically significant changes in expression values (> 2-fold and 
adj. P < 0.05) after 6 hr stimulation with unlabeled A2/NY-ESO-1-specific multimer 
(0.002 µg/ml) separated the samples in two profiles shown above the heatmap. Up-
regulated probes are shown in red, down-regulated in blue. Expression profiles of 
genes from CD8+ T cells transduced with either very low (V49I) or very high 
(wtc51m) affinity TCRs, after 6 hr stimulation (names depicted in red) cluster 
together within the unstimulated (0 hr) profile 1 group. B. 524 genes enriched 
between 0 hr and 6 hr in T cells transduced with TCRs giving maximal function 
(G50A, A97L, DMβ, TMβ) could be classified using GOTermFinder. C. Log2-fold-
changes in the expression level of representative TCR response genes (CRTAM, 
IL2RA), T cell effector cytokine (IFNG) and costimulatory molecules (TNFRSF18 
(GITR), TNFRSF4 (OX40), TNFRSF9 (4-1BB)).  
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Figure 3. Levels of ZAP-70 and ERK 1/2 phosphorylation in SUP-T1 and CD8+ T 
cells engineered with TCRs of incremental affinities. 
A and C. TCR-transduced SUP-T1 T cells (A) and CD8+ T cells (C) were stimulated 
with 10 µg/ml A2/NY-ESO-1157-165 multimers at 37oC for the indicated time-points. 
Total ZAP-70 and ERK 1/2 are shown as internal controls, while α-tubulin (A) or 
actin (C) expression levels were used as loading controls between samples. Data are 
each representative of three independent experiments. TCR-untransduced cells (Ø). 
For CD8+ T cells, all lines were run on the same gel but were noncontiguous. B. To 
allow direct comparison between the different SUP-T1 transduced TCR variants, 
intensity of ZAP-70 and ERK1/2 phosphorylation levels were quantified and 
normalized to α-tubulin. Data from three independent experiments are presented as 
min-to-max bar graphs with average mean lines. 
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Figure 4. Surface expression of costimulatory molecules and co-activatory/inhibitory 
receptors in CD8+ T cells engineered with TCR of incremental affinities. 
A. Surface expression levels of the TNFR-TNFR ligand pairs (i) CD27-CD70 and (ii) 
HVEM-BTLA as well as of CD28 and CD8β are shown in steady-state conditions 
(unstimulated cells). TCR variants are presented in order of increased affinity. Data 
were obtained from ten independent experiments. B. Baseline expression levels of 
Granzyme B and Perforin in CD8+ T cells transduced with TCR variants. Data were 
obtained from 7 independent experiments. A and B. Unpaired two-tailed t test; *** P 
< 0.001; ** 0.001 <  P < 0.01; * 0.01 <  P < 0.05; ns, not significant. 
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Figure 5. PD-1 expression in TCR-engineered CD8+ T cells and functional impact of 
PD-L1 blockade.  
A. Unstimulated at baseline (0h) and Log2 fold change (0-6 hr) expression levels of 
PD1 transcripts as detected in microarray analysis. B. Average surface expression of 
PD-1 (n > nine independent experiments) and its ligand PD-L1 (n > six independent 
experiments) of TCR-engineered CD8+ T. Unpaired two-tailed t test; *** P < 0.001; 
** 0.001 < P <0.01. C. Representative histograms of PD-1 surface expression (in 
MFI) in TCR-engineered CD8+ T cells under steady-state conditions. D. 
Representative histograms of the levels (in MFI) of the degranulation marker LAMP-
1/CD107a in TCR-transduced CD8+ T cells without (control, blue histograms) or 
with PD-L1 blocking antibody (red histograms) prior to 4 hr stimulation with 10 µM 
NY-ESO-1157-165-loaded T2 cells. CD107a degranulation following stimulation with 
unloaded T2 cells is depicted as gray histograms. Graphs below each respective 
histogram represent the direct comparison of TCR stimulation-associated CD107a 
levels without (-) or with PD-L1 blockade (+). Data were obtained from more than 
four independent experiments. Paired two-tailed t test, ** 0.001 < P < 0.01. E. 
Relative CD107a degranulation ratio (in gMFI) obtained in the presence versus the 
absence of PD-L1 blocking antibody. Graphs are depicted as relative CD107 fold-
increase following stimulation with unloaded (left panel) or NY-ESO-1-pulsed (right 
panel) T2 cells. Unpaired two-tailed t test; ** 0.001 <  P < 0.01; * 0.01 <  P < 0.05; 
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Figure 6. Levels of SHP-1 protein and of miR-155 and miR-181a expression in CD8+ 
T cells engineered with TCRs of incremental affinities. 
A. Unstimulated at baseline (0h) and Log2 fold change (0-6 hr difference) expression 
levels of SHP1 transcripts as detected in microarray analysis. B and C. TCR-
transduced CD8+ T cells (B) and SUP-T1 cells (C) were stimulated with 10 µg/ml 
A2/NY-ESO-1157-165 multimers for the indicated time-points and assessed for SHP-1 
phosphorylation and total SHP-1 levels by Western blotting. Actin (B) or α-tubulin 
(C) expression levels were used as loading controls between samples. Data are each 
representative of three independent experiments. For CD8+ transduced T cell 
samples, all lines were run on the same gel, but were noncontiguous. TCR-
untransduced; Ø. D. To allow direct comparison between the engineered SUP-T1 
cells, intensity of SHP-1 phosphorylation and of total SHP-1 levels were quantified 
and normalized to α-tubulin (n = 3 independent experiments). E. Expression levels of 
miR-181a and miR-155 were determined by qRT-PCR in TCR-transduced CD8+ T 
cells following stimulation with 0.1µg/ml A2/NY-ESO-1157-165 multimers at the 
indicated time-points. Data represent relative expression compared to RNU48 control 
and are representative of three independent experiments. Pri-miR-155 (BIC) mRNA 
expression values (inset) were retrieved from the microarray analysis. 
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Figure 7. Pharmacological inhibition of SHP-1 phosphatase in TCR engineered 
CD8+ T cells  
A. Representative histograms of the levels (in MFI) of LAMP-1/CD107a expression 
in TCR-transduced CD8+ T cells without (control, blue histograms) or with SHP-1 
inhibition by SSG (red histograms) prior to 4 hr stimulation with 10 µM NY-ESO-
1157-165-loaded T2 cells. CD107a degranulation following stimulation with unloaded 
T2 cells is depicted as gray histograms. Graphs below each respective histogram 
represent the direct comparison of TCR stimulation-associated CD107a levels 
without (-) or with SHP-1 inhibition (+). Paired two-tailed t test; *** P < 0.001; ** 
0.001 < P < 0.01; * 0.01 < P < 0.05. Data were obtained from six independent 
experiments. B. Relative CD107a degranulation ratio (in gMFI) obtained in the 
presence versus the absence of SHP-1 inhibition compound SSG. Graphs show 
relative CD107 fold-increase following stimulation with unloaded (left panel) or NY-
ESO-1-pulsed (right panel) T2 cells. C. Melanoma cell killing by TCR-transduced 
CD8+ T cells without (mock) or with SSG treatment for 4 days. Tumor reactivity for 
the melanoma cell line Me 275 was assessed in a functional 4h 51Cr release assay. D. 
Relative 51Cr count-per-minute (CPM) ratio with and without SSG at the indicated 
E:T ratios. Unpaired two-tailed t test; *** P < 0.001; ** 0.001 <  P < 0.01; * 0.01 <  P 














SUPPLEMENTAL DATA      Hebeisen et al. 
 
SUPPLEMENTAL METHODS 
Flow cytometry immunofluorescence analysis  
The following fluorophore-conjugated antibodies were used for staining of surface 
costimulatory molecules and co-activatory/inhibitory receptors for 20 min at 4oC; 
CD27 (APC-Alexa780; eBioscience), CD70 (FITC; BD Biosciences), HVEM (APC; 
Biolegend), BTLA (PE; BD Biosciences), CD28 (FITC; BD Biosciences), CD8α 
(PerCP-Cy5.5; Biolegend), CD8β (PE; Beckman Coulter), PD-1 (PerCP-eFl710; 
eBioscience), PD-L1 (PE-Cy7; BD Bioscience), PD-L2 (APC; Biolegend), Granzyme 
B (FITC; Biolegend) and Perforin (APC, Biolegend). Appropriate isotype controls 
were used to define negative populations. 
 
Calcium flux assays upon NY-ESO-1 peptide loaded T2 cells 
15x104 T2 cells pulsed with increasing concentrations of NY-ESO157-165 peptide were 
used as APCs and brought in contact with 5x104 (E:T ratio 1:3), 2 µM Indo1-AM 
loaded TCR-transduced primary CD8+ T cells through a 10 seconds 1400 rpm 
centrifugation before immediate cytometric recording. Intracellular Ca2+ flux was 
recorded under UV excitation and constant temperature of 37ºC using a thermostat 
device on a LSR II SORP (BD Biosciences) flow cytometer. Indo-1(violet)/Indo-




Total RNA was isolated using NucleoSpin® RNA II extraction protocols (Macherey-
Nagel, Bietlenheim, Germany) and RNA was of high quality and integrity, as verified 
through Agilent 2100 Bioanalyser platform (Agilent Technologies, Waldbronn, 
Germany). 1µg of RNA was used for T7-based amplification and Cy3 labeling. 
Samples were hybridized to Agilent Whole Human Genome Oligo Microarrays 
4x44K and scanned using the Agilent microarray scanner system (Agilent). The 
Agilent Feature Extraction Software was used for readout and processing of image 
 2 
files. Background correction, filtering of data, and quantile normalization were done 
using R and the Agi4x44PreProcess software package as described in the package 
manual. The Limma software package was used to identify differentially expressed 
genes and to calculate the log2 fold change. Gene probes were considered significant 
if their P value corrected for a FDR of 0.05 was P < 0.05. Fold change expression 
between 0 hr and 6 hr detected in T cells variants generating optimal function (G50A, 
A97L, DMβ and TMβ) were converted into UniProt IDs using BioMart and then 
classified into broad gene ontology (GO) terms using the GOTermFinder 
(http://go.princeton.edu/cgi-bin/GOTermFinder). The log2 fold changes of probes 
assigned to the same GO-term were averaged in absolute value to yield a general 
measure of expression change independent of its direction.  
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SUPPLEMENTAL FIGURE LEGENDS 
 
Supplemental Figure 1. Calcium mobilization assays in primary CD8+ T cells 
engineered with affinity-optimized TCR variants 
A. A representative kinetic analysis of Ca2+ mobilization in CD8+ T cells transduced 
with affinity-optimized TCR variants after stimulation with T2 cells (APC) loaded 
with increasing peptide concentrations. Acquisition of Ca2+ influx was performed 
over time in the following order: (i) without APC, (ii) with APC loaded with 
increasing concentrations of NY-ESO-1 157-165 peptide (from 0 to 5 µM) and (iii) with 
ionomycin as a positive control. B. The mean Ca2+ influx values for all independent 
experiments (n > 3) for each engineered CD8+ T cells following stimulation at the 
indicated peptide concentration (no peptide, 0.001 to 1 µM). Ca2+ mobilization 
obtained after stimulation with NY-ESO-1-expressing Me 290 or Me 275 (HLA-
A2+/NY-ESO+) tumor cell lines in TCR WT-transduced T cells are highlighted as a 
shaded gray box on the graphs, and indicate that the 0.01 µM peptide-loaded T2 
stimulation condition resembles closely to the natural antigen presentation by tumor 
cell lines. Of note, no Ca2+ flux is detected upon stimulation of untransduced CD8+ T 
cells (no TCR) or upon stimulation of WT NY-ESO-1-transduced T cells with Flu-
specific peptide (WT/Flu). Maximal Ca2+ flux after ionomycin stimulation indicates 
equal capacity to mobilize calcium in all T cell variants. Importantly, similar data 
were obtained independently of stimulation with either peptide-pulsed APCs (as 




Supplemental Figure 2. Surface levels of TCR expression and TCR/CD8 down-
regulation in engineered SUP-T1 and CD8+ T cells  
A. Percentage of SUP-T1 cells expressing affinity-optimized NY-ESO-1-specific 
TCRs as detected by NY-ESO-1157-165-specific multimer staining (left panel). Surface 
expression levels (in MFI) of TCR β-chain BV13.1 (middle) and total αβTCR (right) 
are shown for all SUP-T1 transduced cells. B. Surface staining of CD8 and TCR β-
chain BV13.1 on CD8+ T cells engineered with TCR variants in the absence (un-
stimulated) or following stimulation with 0.1 µg/ml unlabeled HLA-A2/NY-ESO-
1157-165 specific multimers for 4 hours. Representative dot-plots showing the 
proportion of reduced CD8 expression (CD8 low) compared to CD8 high expression 
for all engineered T cells. Of note, increased CD8 down-modulation was observed for 
T cells expressing optimal TCR affinities (e.g. A97L, DMβ and TMβ), in contrast to 
supraphysiological T cells (e.g. TMα, wtc51m). C and D. Down-regulation of TCR 
expression on engineered CD8+ T cells was assessed in the absence (-) or presence (+) 
of 10 µM peptide-loaded T2 (C) or 0.1 µg/ml unlabeled A2/ NY-ESO-1157-165 specific 
multimers (D) for 4 hours. TCR down-regulation was revealed by reduced multimer 
fluorescence (C) or TCR β-chain BV13.1 staining (D). Importantly, similar results 
were obtained independently following stimulation with either peptide-pulsed T2 cells 




Supplemental Figure 3. Global gene expression profiles of CD8+ T cells engineered 
with affinity-optimized TCR variants 
A genome-wide microarray analysis was performed on primary CD8+ T cells 
expressing TCR variants following low dose (0.002 µg/ml) of HLA-A2/ NY-ESO-
1157-165 specific multimer stimulation as described in the main manuscript. We 
identified 524 genes enriched between 0 hr and 6 hr in T cells transduced with 
optimal TCR variants (G50A, A97L, DMβ, TMβ), which could be further classified 
according to GO terms (Figure 2, main manuscript). Using the same list of enriched 
genes, we also assessed the average log2 gene expression variance for each engineered 
T cell variant at baseline (un-stimulated) and per GO term. Variance is defined as the 
difference from the mean on a log2 scale. These results show that in contrast to 
stimulated CD8+ T cells, no major changes in the GO terms (immune response, T cell 
activation, cell proliferation, signaling, gene expression and apoptosis) were observed 
within un-stimulated T cells and among the various TCR-transduced T cells. 
However, it should be noted that a marginal trend in gene expression over-
representation was sometimes found for the T cells bearing highest TCR affinities 
(e.g. TMα and wtc51m). Moreover, we also noticed small fluctuations, particularly 
when we compared the T cell variants for the GO term “gene expression” and “cell 
proliferation”, likely reflecting differences in culture conditions occurring during the 




Supplemental Figure 4. Levels of ZAP-70 and ERK 1/2 protein expression and 
phosphorylation in engineered T cells with affinity-optimized TCR variants  
A. TCR-transduced SUP-T1 T cells and CD8+ T cells were stimulated with 10 µg/ml 
HLA-A2/NY-ESO-1157-165 multimers at 37oC for the indicated time-points and 
assessed for total ZAP-70 and total ERK1/2 levels by Western blotting, in parallel to 
the data presented in Figure 3A and C (main manuscript). Tubulin (SUP-T1) or actin 
(CD8+) expression levels were used as loading controls between samples and time-
points. TCR-untransduced cells; Ø. n.d., not done. B. To allow direct comparison 
between TCR-engineered SUP-T1 cells, intensity of total ZAP-70 and total ERK1/2 
levels were quantified and normalized to α-tubulin. Data from 3 independent 
experiments are presented as min-to-max bar graphs with average mean lines. TCR 
variants are presented in order of increased affinity. Baseline represents the un-
stimulated T cells. C. Example of another representative western blot analysis on 
stimulated CD8+ T cells. ZAP-70 and ERK1/2 phosphorylation levels as well as total 
ZAP-70 and ERK1/2 are depicted at the indicated time-points following antigen-
specific stimulation.  
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Supplemental Figure 5. Levels of SHP-1 phosphorylation and of total SHP-2 protein 
expression in engineered T cells with affinity-optimized TCR variants  
A. Actin (for CD8+ T cells) or α-tubulin (for SUP-T1 cells) expression levels were 
used as loading controls between samples and time-points, and were performed in 
parallel to the data presented in Figure 6B and C (main manuscript). B. TCR-
transduced CD8+ T cells and SUP-T1 cells were stimulated with 10 µg/ml HLA-
A2/NY-ESO-1157-165 multimers at 37oC for the indicated time-points and assessed for 
SHP-1 phosphorylation levels. TCR-untransduced cells; Ø. C. Un-stimulated at 
baseline (0h) and Log2 fold change (0-6 hr difference) expression levels of SHP2 
transcripts as detected in microarray analysis. D and E. TCR-transduced CD8+ T cells 
(D) and SUP-T1 cells (E) were stimulated with 10 µg/ml A2/NY-ESO-1157-165 
multimers for the indicated time-points and assessed for total SHP-2 protein 
expression levels by Western blotting. We used for SHP-2 protein expression analysis 
the following antibody: rabbit anti-SHP-2 (C-18) (Santa Cruz Biotechnology, Inc). 
Actin (for CD8+ T cells) or α-tubulin (for SUP-T1 cells) expression levels were used 
as loading controls between samples. Baseline represents the un-stimulated T cells. 
For CD8+ transduced T cell samples, all lines were run on the same gel, but were 






Supplemental Table 1. Relative affinities of the sequence-optimized A2/NY-ESO-1 
specific TCR variants 
TCR AV23.1-BV13.1a CDR modification Relative affinityb 
wtc51mc CDR2β 1427 
QMα CDR2+3β; CDR2α 153 
TMα CDR2β; CDR2α 54 
TMβ CDR2+3β 24 
DMβ CDR2β 11 
A97L CDR3β 8 
G50A CDR2β 5 
WTd none 1 
V49I CDR2β N/A 
aThe NY-ESO-1-specific TCR AV23.1-BV13.1 was optimized by in silico modeling, through 
amino acid substitutions in CDR2α and/or CDR2β and/or CDR3β loops as previously 
described (1). 
bSequence-optimized TCR affinities are indicated in relative fold-increase from the WT TCR 
(KD, 21.4 µM), as characterized recently (2). A sub-physiological, weak-binding TCR (V49I), 
with an estimated affinity of > 100 µM to pMHC was included. N/A, not applicable. 
cThe modified wtc51 TCR variant, comprises the WT TCR sequences with four amino acid 
replacements within the CDR2β loop (3), resulting in the drastic increase of its affinity 
towards pMHC. 
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